Boston Scientific (BSX) Surges Amid Penumbra Acquisition, Analysts Bullish on Future Growth

Saturday, Jan 31, 2026 8:55 pm ET1min read
BSX--
PEN--

Boston Scientific (BSX) has garnered bullish views from analysts after acquiring Penumbra. Richard Newitter from Truist Securities reiterated a Buy rating and a $120 price target, implying a 28% upside. The acquisition is expected to bolster the company's durability and support double-digit revenue and EPS growth prospects. Morgan Stanley also reiterated its positive view on the company, citing "clear catalysts" making the stock valuation highly attractive.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet